id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-N-0830-0008,FDA,FDA-2011-N-0830,"Abbreviated New Drug Applications and 505(b)(2) Applications; Extension
of Comment Period",Proposed Rule,Extension of Comment Period,2015-04-24T04:00:00Z,2015,4,2015-04-24T04:00:00Z,2015-06-09T03:59:59Z,2015-06-10T01:30:47Z,2015-09523,0,0,0900006481ab8547
FDA-2011-N-0830-0007,FDA,FDA-2011-N-0830,Request for Extension from Generic Pharmaceutical Association (GPhA),Other,Request for Extension,2015-04-03T04:00:00Z,2015,4,2015-04-03T04:00:00Z,,2015-04-03T14:28:29Z,,0,0,0900006481a4313f
FDA-2011-N-0830-0006,FDA,FDA-2011-N-0830,Request for Extension from Teva Pharmaceuticals,Other,Request for Extension,2015-04-03T04:00:00Z,2015,4,2015-04-03T04:00:00Z,,2015-04-03T14:19:47Z,,0,0,0900006481a3f782
FDA-2011-N-0830-0005,FDA,FDA-2011-N-0830,Abbreviated New Drug Applications and 505(b)(2) Applications,Proposed Rule,Correction,2015-03-13T04:00:00Z,2015,3,2015-03-13T04:00:00Z,,2015-03-13T16:28:12Z,C1-2015-01666,0,0,0900006481a4296e
FDA-2011-N-0830-0004,FDA,FDA-2011-N-0830,"Reference 2 - Pharmaceutical Preparation Manufacturing 2002, Economic Census Manufacturing Industry Series re Abbreviated New Drug Applications and 505(b)(2) Applications",Supporting & Related Material,Background Material,2015-02-06T05:00:00Z,2015,2,,,2015-02-06T16:37:42Z,,0,0,09000064819f8606
FDA-2011-N-0830-0002,FDA,FDA-2011-N-0830,List of References re Abbreviated New Drug Applications and 505(b)(2) Applications,Supporting & Related Material,Background Material,2015-02-06T05:00:00Z,2015,2,,,2015-02-06T16:37:25Z,,0,0,09000064819f8604
FDA-2011-N-0830-0001,FDA,FDA-2011-N-0830,Abbreviated New Drug Applications and 505(b)(2) Applications,Proposed Rule,Notice of Proposed Rulemaking (NPRM),2015-02-06T05:00:00Z,2015,2,2015-02-06T05:00:00Z,2015-05-08T03:59:59Z,2015-04-10T02:06:25Z,2015-01666,0,0,09000064819f78d2
FDA-2011-N-0830-0003,FDA,FDA-2011-N-0830,Reference 1 - ANDAs and 505(b)(2) Applications Docket No. FDA-2011-N-0830 Preliminary Regulatory Impact Analysis Initial Regulatory Flexibility Analysis Unfunded Mandates Reform Act Analysis re Abbreviated New Drug Applications and 505(b)(2) Applications,Supporting & Related Material,Background Material,2015-02-06T05:00:00Z,2015,2,,,2015-02-06T16:37:36Z,,0,0,09000064819f8605